Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.31 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3760397 | 0.78 | — | — | |
| SCHEMBL8844292 | 0.76 | — | — | |
| SCHEMBL261605 | 0.76 | — | — | |
| SCHEMBL9936404 | 0.74 | KMT2A (0.45) | NPC1RAB9AKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL29014454 | 0.74 | NPC1 (0.44) | NPC1RAB9AKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL2321138 | 0.74 | — | — | |
| SCHEMBL98748 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL26916941 | 0.72 | NPC1 (0.49) | NPC1RAB9AKMT2AALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL26916942 | 0.72 | NPC1 (0.49) | NPC1RAB9AKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL1324 | 0.72 | NPC1 (0.62) | NPC1RAB9AKMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9558863-B2 | Electrically conductive polymers with enhanced conductivity | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2017-01-31 | — | — | US | disclosed |
| US-9243111-B2 | Water-soluble electrically conductive polymers | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2016-01-26 | — | — | US | disclosed |
| US-20150083977-A1 | ELECTRICALLY CONDUCTIVE POLYMERS WITH ENHANCED CONDUCTIVITY | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2015-03-26 | — | — | US | disclosed |
| US-8920681-B2 | Electrically conductive polymers with enhanced conductivity | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2014-12-30 | — | — | US | disclosed |
| US-20140077135-A1 | WATER-SOLUBLE ELECTRICALLY CONDUCTIVE POLYMERS | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2014-03-20 | — | — | US | disclosed |
| US-8536300-B2 | Photocrosslinkable electrically conductive polymers | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2013-09-17 | — | — | US | disclosed |
| US-8535571-B2 | Water-soluble electrically conductive polymers | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2013-09-17 | — | — | US | disclosed |
| US-8134023-B2 | Preparation of pregabalin and related compounds | PFIZER INC (US) | 2012-03-13 | — | — | US | disclosed |
| US-20120015412-A1 | Preparation of Pregabalin and Related Compounds | PFIZER INC | 2012-01-19 | — | — | US | disclosed |
| US-8044227-B2 | Preparation of pregabalin and related compounds | PFIZER INC. (US) | 2011-10-25 | — | — | US | disclosed |
| EP-1863780-A1 | PREPARATION OF OPTICALLY PURE BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | Pharmacia & Upjohn Company LLC (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1831154-A2 | PREPARATION OF PREGABALIN AND RELATED COMPOUNDS | Warner-Lambert Company LLC (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070141684-A1 | Preparation of gamma-amino acids having affinity for the alpha-2-delta protein | PFIZER INC | 2007-06-21 | — | — | US | disclosed |
| EP-1768952-A2 | PREPARATION OF BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | Warner-Lambert Company LLC (US) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006100568-A1 | PREPARATION OF OPTICALLY PURE BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006100606-A2 | PREPARATION OF BETA-AMINO ACID PRECURSORS VIA INDIUM (III) MEDIATED MARKOVNIKOV ADDITION AND KNOEVENAGEL CONDENSATION | WARNER-LAMBERT COMPANY LLC (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006008612-A2 | PREPARATION OF BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006000904-A2 | PREPARATION OF PREGABALIN AND RELATED COMPOUNDS | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050283023-A1 | Preparation of pregabalin and related compounds | HU SHANGHUI | 2005-12-22 | — | — | US | disclosed |
| US-20050228190-A1 | C1-symmetric bisphosphine ligands and their use in the asymmetric synthesis of pregabalin | BAO JIAN | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070141684-A1 | Preparation of gamma-amino acids having affinity for the alpha-2-delta protein | SCN2A, CACNG2, SCN1A | NPC1 2810/4885RAB9A 1331/4885KMT2A 3394/4885 |
| US-20050283023-A1 | Preparation of pregabalin and related compounds | GABRE, GABRG1, GABRA6 | NPC1 3760/4885RAB9A 2336/4885KMT2A 2049/4885 |
| US-20050228190-A1 | C1-symmetric bisphosphine ligands and their use in the asymmetric synthesis of pregabalin | GABRA5, CNR1, GABRE | NPC1 2524/4885RAB9A 2968/4885KMT2A 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.